Orphan drugs push approvals to new high in 2015

FDA Ibrance palbociclib from Pfizer Inc. (NYSE:PFE), which FDA approved in combination with letrozole for first-line treatment of postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer, had breakthrough therapy but not Orphan drug designation. ...